Identification of prognostic markers in ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Identification of prognostic markers in diffuse midline gliomas h3k27m-mutant
Auteur(s) :
Dufour, Charlotte [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Perbet, Romain [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Leblond, Pierre [Auteur]
Miniaturisation pour la Synthèse, l’Analyse et la Protéomique - UAR 3290 [MSAP]
Vasseur, Romain [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Stechly, Laurence [Auteur]
Institut de Microbiologie [CHRU Lille]
Pierache, Adeline [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Reyns, Nicolas [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Thérapies Lasers Assistées par l'Image pour l'Oncologie (ONCO-THAI) - U1189
Touzet, Gustavo [Auteur]
Département de Neurochirurgie[Lille]
Le Rhun, Emilie [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Vinchon, Matthieu [Auteur]
Maladies RAres du DEveloppement embryonnaire et du MEtabolisme : du Phénotype au Génotype et à la Fonction - ULR 7364 [RADEME]
Maladies Rares du Développement : Génétique, Régulation et Protéomique (RADEME) - ULR 7364
Maurage, Claude-Alain [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Escande, Fabienne [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Renaud, Florence [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Perbet, Romain [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Leblond, Pierre [Auteur]
Miniaturisation pour la Synthèse, l’Analyse et la Protéomique - UAR 3290 [MSAP]
Vasseur, Romain [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Stechly, Laurence [Auteur]
Institut de Microbiologie [CHRU Lille]
Pierache, Adeline [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Reyns, Nicolas [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Thérapies Lasers Assistées par l'Image pour l'Oncologie (ONCO-THAI) - U1189
Touzet, Gustavo [Auteur]
Département de Neurochirurgie[Lille]
Le Rhun, Emilie [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Vinchon, Matthieu [Auteur]
Maladies RAres du DEveloppement embryonnaire et du MEtabolisme : du Phénotype au Génotype et à la Fonction - ULR 7364 [RADEME]
Maladies Rares du Développement : Génétique, Régulation et Protéomique (RADEME) - ULR 7364
Maurage, Claude-Alain [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Escande, Fabienne [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Renaud, Florence [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Titre de la revue :
Brain pathology (Zurich, Switzerland)
Nom court de la revue :
Brain Pathol.
Numéro :
30
Pagination :
179-190
Date de publication :
2019-07-26
ISSN :
1750-3639
Mot(s)-clé(s) :
prognostic markers
molecular alterations
diffuse midline gliomas
chomosomal profile
translational study
molecular alterations
diffuse midline gliomas
chomosomal profile
translational study
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Pediatric diffuse midline gliomas are devastating diseases. Among them, diffuse midline gliomas H3K27M-mutant are associated with worse prognosis. However, recent studies have highlighted significant differences in clinical ...
Lire la suite >Pediatric diffuse midline gliomas are devastating diseases. Among them, diffuse midline gliomas H3K27M-mutant are associated with worse prognosis. However, recent studies have highlighted significant differences in clinical behavior and biological alterations within this specific subgroup. In this context, simple markers are needed to refine the prognosis of diffuse midline gliomas H3K27M-mutant and guide the clinical management of patients. The aims of this study were (i) to describe the molecular, immunohistochemical and, especially, chromosomal features of a cohort of diffuse midline gliomas and (ii) to focus on H3K27M-mutant tumors to identify new prognostic markers. Patients were retrospectively selected from 2001 to 2017. Tumor samples were analyzed by immunohistochemistry (including H3K27me3, EGFR, c-MET and p53), next-generation sequencing and comparative genomic hybridization array. Forty-nine patients were included in the study. The median age at diagnosis was 9 years, and the median overall survival (OS) was 9.4 months. H3F3A or HIST1H3B mutations were identified in 80% of the samples. Within the H3K27M-mutant tumors, PDGFRA amplification, loss of 17p and a complex chromosomal profile were significantly associated with worse survival. Three prognostic markers were identified in diffuse midline gliomas H3K27M-mutant: PDGFRA amplification, loss of 17p and a complex chromosomal profile. These markers are easy to detect in daily practice and should be considered to refine the prognosis of this entity.Lire moins >
Lire la suite >Pediatric diffuse midline gliomas are devastating diseases. Among them, diffuse midline gliomas H3K27M-mutant are associated with worse prognosis. However, recent studies have highlighted significant differences in clinical behavior and biological alterations within this specific subgroup. In this context, simple markers are needed to refine the prognosis of diffuse midline gliomas H3K27M-mutant and guide the clinical management of patients. The aims of this study were (i) to describe the molecular, immunohistochemical and, especially, chromosomal features of a cohort of diffuse midline gliomas and (ii) to focus on H3K27M-mutant tumors to identify new prognostic markers. Patients were retrospectively selected from 2001 to 2017. Tumor samples were analyzed by immunohistochemistry (including H3K27me3, EGFR, c-MET and p53), next-generation sequencing and comparative genomic hybridization array. Forty-nine patients were included in the study. The median age at diagnosis was 9 years, and the median overall survival (OS) was 9.4 months. H3F3A or HIST1H3B mutations were identified in 80% of the samples. Within the H3K27M-mutant tumors, PDGFRA amplification, loss of 17p and a complex chromosomal profile were significantly associated with worse survival. Three prognostic markers were identified in diffuse midline gliomas H3K27M-mutant: PDGFRA amplification, loss of 17p and a complex chromosomal profile. These markers are easy to detect in daily practice and should be considered to refine the prognosis of this entity.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
- Lille Neurosciences & Cognition (LilNCog) - U 1172
- Maladies Rares du Développement : Génétique, Régulation et Protéomique (RADEME) - ULR 7364
- Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
- Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
- Thérapies Lasers Assistées par l'Image pour l'Oncologie (ONCO-THAI) - U1189
Équipe(s) de recherche :
Développement et plasticité du cerveau neuro-endocrine
Date de dépôt :
2021-06-23T13:43:20Z
2021-11-10T11:14:13Z
2021-11-10T11:16:45Z
2022-01-20T08:27:34Z
2023-04-21T15:41:55Z
2021-11-10T11:14:13Z
2021-11-10T11:16:45Z
2022-01-20T08:27:34Z
2023-04-21T15:41:55Z